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Adaptive immune systemThe link between inﬂammation and colorectal cancer development is becoming increasingly clear. It had long
been recognized that patients with inﬂammatory bowel disease are at an increased risk of colon cancer.
Evidence from experimental animals now also implicates the innate immune system in the development of
sporadically occurring intestinal adenomas, the precursors to colorectal cancer. Here we discuss the
interaction between the immune system and the adenoma to carcinoma sequence with a special emphasis on
the role of mast cells which may play a key role in adenoma development. This article is part of a Special Issue
entitled: Mast cells in inﬂammation.ells in inﬂammation.
logy & Hepatology, Academic
en Brink).
l rights reserved.© 2010 Elsevier B.V. All rights reserved.The intimate link between a developing colorectal carcinoma and
our immune system has been increasingly recognized in recent
years. It has long been known that patients with longstanding
inﬂammatory bowel disease are at increased risk of colorectal cancer
development, an example that is often used to illustrate the link
between chronic inﬂammation and cancer development. However
the relationship between immune cells and a nascent colorectal
cancer are more complex with some cells exerting protective effects
and others playing a tumor promoting role. Also a recent insight is
that the interaction between the immune system and cancer
development is not restricted to patients with inﬂammatory bowel
disease but seems equally important for sporadic colorectal cancer
development. Here we will brieﬂy review some important aspects
of the interaction of the immune system and colorectal cancer
development and then examine the role of mast cells in more
detail.
1. The link between inﬂammatory bowel disease and colorectal
cancer development
Patients with chronic inﬂammatory bowel disease are at an
increased risk of colorectal cancer development. In patients with
ulcerative colitis the risk of cancer development correlates strongly
with the duration and extent of disease [12] and in patients with
Crohn's disease risk of colorectal cancer is only increased in patients
with colonic disease [11]. These associations strongly suggest directinteraction between the inﬂammatory cells in the lamina propria and
the epithelial cells that go through the adenoma to carcinoma
sequence. A metaanalysis suggested that the cumulative incidence
of colon cancer in patients with inﬂammatory bowel disease may be
as much as 2%, 8% and 20% at 10, 20 and 30 years of disease [10]
however it is widely debated if these ﬁgures are representative of the
whole population of patients with ulcerative colitis or more reﬂective
of the risk of more severely affected patients seen in tertiary referral
centers. It is not known at what stage of the adenoma to carcinoma
sequence the inﬂammatory cells act. For example there are no solid
data on the prevalence or size of adenomas in patients with
inﬂammatory bowel disease compared to the general population. It
is therefore not clear if the mucosal inﬂammation acts on adenoma
initiation, progression or both or acts to promote the adenoma to
carcinoma transition. It is clear however that the adenoma to
carcinoma sequence is distinct from that in sporadic colorectal
carcinoma development. Cancers in inﬂammatory bowel disease
have both a distinct morphology with a high prevalence of ﬂat
dysplastic lesions [18] and a distinct sequence of mutations for
example with early and frequent loss of p53 [19].
2. Immunity and sporadic colon cancer development
As it was found that leukocyte inﬁltration in colorectal cancer is
associated with a better prognosis [21,43] it may seem to the casual
observer that there is a distinct role for immunity in patients with
inﬂammatory bowel disease and sporadic colorectal cancer devel-
opment. However, it is important to realize that the factors that
affect cancer prognosis are very different from those that affect
cancer incidence. A well known example is the role of TGFβ
signaling which acts as a tumor suppressor in the early stages of
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The fact that polyp incidence and progression are two different
things can be well observed in the Apcmin/+ mouse model where
modulators rarely inﬂuence both polyp incidence and size (pro-
gression) but mostly affect one or the other. Inﬂammatory cells may
similarly have very different effects on cancer incidence and its
progression and therefore differentially affect the chance of
developing cancer and its prognosis.
The realization that inﬂammation may not only affect colon cancer
prognosis but also play a key role in sporadic colorectal cancer
incidence is of recent years. Thus far the evidence is mainly from
experimental animals and suggests distinct roles for the innate and
adaptive immune system.
2.1. Adaptive immunity
The adaptive immune system consists of T and B lymphocytes
which are specialized in recognizing ‘self’ form ‘non-self’ by
recognition of highly speciﬁc epitopes. Recognition of ‘non-self’
seems to extend to protection against tumor development. Lympho-
cytes are able to recognize and contain or destruct nascent tumors in a
process called cancer immunoediting [9]. Experimental evidence in
mice suggests that this process is important in the protection against
colorectal carcinogenesis. Recombination activating gene-2 mutant
mice which are entirely devoid of both B and T cells are more
susceptible to tumorigenesis in a variety of experimental models and
spontaneously develop intestinal adenomas and carcinomas with age
[39]. A few lymphocytes are probably enough to exert a tumor
protective effect as athymic nudemice which are largely depleted of T
cells and B cells but still contain some lymphocytes do not show
increased susceptibility to carcinogenesis [42]. A link between
adaptive immunity and colorectal cancer development in humans is
suggested by the observation that colon cancer seems to be more
frequent in liver transplant patients [41] that are treated with
sufﬁcient immunosuppressants to prevent ‘non-self’ recognition of
the transplanted organ.
2.2. Innate immunity
Cells of the innate immune system include both leukocytes such as
mast cells, macrophages and dendritic cells and epithelial cells. These
cells recognize small structural motifs within a group of pathogens, so
called pathogen associatedmolecular patterns, with the use of pattern
recognition receptors. The pattern recognition receptors are highly
conserved in evolution, for example the toll like receptor family and
its key intracellular signaling components have been conserved from
fruit ﬂy to humans [27]. The importance of innate immunity in driving
intestinal adenoma development ﬁrst became evident in the Apcmin/+
mouse model. These mice are heterozygous for a mutation in the Apc
gene that also acts as an initiatingmutation in many human colorectal
cancers and develop multiple small intestinal adenomas (see below).
When Rakoff-Nahoum et al. crossed these mice with a mouse that
lacked Myd88, the protein that links the Toll like receptors to NF-
kappaB signaling, it became evident that these mice had substantially
reduced size and numbers of adenomas [36]. Lee et al. subsequently
performed bone marrow transplantations show that the tumor
promoting effect of Myd88 signaling is not in the hematopoietic
cells but dependent on a non transplanted cell type [26]. Although the
authors of the study conclude that adenoma formation depends on
epithelial Myd88 an alternative could be Myd88 signaling in stromal
cells of non-hematopoietic origin such as (myo)ﬁbroblasts, endothe-
lial cells or smooth muscle cells. The relevance of pattern recognition
receptor signaling in colorectal carcinogenesis in humans remains
unclear. For example, single nucleotide polymorphisms in pattern
recognition receptors such as NOD2 and TLR4 are clearly associatedwith risk of inﬂammatory bowel disease but no such associations have
been reported for sporadic colorectal cancer.
Even though Lee et al. found that Myd88 dependent adenoma
formation in the Apcmin/+mousemay not depend on tumor associated
leukocytes it is clear that macrophages may play an important role at
different stages of the adenoma to carcinoma sequence. Oguma et al.
used the Colony stimulating factor-1 mutant (Csf1−/−) or op/opmouse
to probe the role of macrophages in intestinal adenoma development.
The Csf1−/− mouse has a defect in monocyte and macrophage
maturation [46] and strongly reduced numbers of mucosal macro-
phages in the gastrointestinal tract [4]. Polyp number was slightly
reduced in Apc mutant op/op mice and that there was a more
pronounced reduction in the growth of the adenomas suggesting that
macrophages may play a role in adenoma growth. An important
aspect of adenoma inﬁltrating macrophages is that they are the major
source of COX-2 in both humans [7,15] and Apcmin/+ mice [16]. The
efﬁcacy of COX-2 selective NSAIDs in adenoma prevention trials [2,3]
is therefore at least circumstantial evidence for an important role of
macrophages in adenoma growth in humans. The role of macrophages
in adenoma initiation, growth and progression to cancer is probably
complex given the many subtypes of macrophages that are now
recognized [31]. For example it may be that ‘classically activated’
macrophages which act to stimulate the host defense enhance anti-
tumor immunity whereas alternatively activated macrophages
(which play a key role in wound healing) are more likely to promote
tumor invasion and angiogenesis.
Recent work for different laboratories suggests that in addition to
macrophages, mast cells which accumulate in intestinal adenomas
(Fig. 1) may also affect colorectal carcinogenesis. Results are
conﬂicting and will be discussed in more detail here.
3. Mast cells and colorectal cancer in humans
Mast cells are tissue resident myeloid cells that are generally
divided into two distinct types, connective tissue and mucosal mast
cells. Mucosal mast cells populate the mesenchyme underlying the
epithelium of the airways and gastrointestinal tract. They contain
cytoplasmic granules ﬁlled with mediators of inﬂammation such as
cytokines, proteases, histamine, serotonin and eicosanoids. Mast cells
degranulate upon activation by pattern recognition receptors or after
cross linking of the IgE receptor. Histamine is one of the mast cell
released factors that has attracted most attention in the context of
colorectal cancer. Investigators of a trial that treated patients with the
histamine antagonist Cimetidine for 7 days perioperatively reported a
strong survival beneﬁt from the Cimetidine treatment [1] and an
investigator of a trial in which Cimitedine was studied for symptom-
atic relief of colon cancer patients reported a similar survival beneﬁt
[29]. The inhibition of histamine signaling in such a short time
window was believed to inﬂuence the immunological response to
colon cancer cells. However a subsequent trial did not replicate this
strong effect [23] and no further clinical trials have been performed.
Histamine has also been reported to stimulate canonical Wnt
signaling, the driving force of adenoma formation (see below), in
vitro [8] but no data exist to suggest that histamine alters Wnt
signaling in vivo. Also, short perioperative treatments with histamine
antagonists would be unlikely to affect colon cancer survival via
effects on Wnt signaling if such a survival beneﬁt would exist.
There are no data that examine a potential association between
mast cells prevalence and colon cancer incidence in humans. Although
some studies have assessed a potential correlation between mast cell
inﬁltration and colon cancer progression most are very small and
therefore not very informative. In one large cohort of colorectal cancer
patients it was shown that high mast cell counts are an independent
prognosticator after multivariate analysis associated with a favorable
prognosis [34]. As work in mouse models of colorectal cancer so far
depends on a frequently used mouse with a naturally occurring
Fig. 1. A Leder stain detects very rare mast cells in the normal mouse intestine, clear accumulation of mast cells can be observed in an adenoma of an Apc+/− mouse.
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in the studies.4. Mast cell deﬁcient mice
Much of the research in the mast cell ﬁeld depends on the use of
WBB6F1 and later also C57/Bl6 mice with naturally occurring
mutations at the at the Dominant Spotting (W) locus on chromosome
5 and the Steel (Sl) locus on chromosome 10 [45]. The W locus was
shown to encode receptor c-Kit [5,13] whereas the Sl locus encodes
its ligand kit ligand (Kitl) [47]. Although many different Sl and W
alleles are homozygous lethal mice that carry two different steel
(Kitlsl/Kitlsl−d) or W (KitW/KitW−v) alleles are viable and used in most
experiments. These mice have a similar phenotype characterized by
white coat color due to a failure in melanocyte differentiation,
sterility caused by a lack of germ cell survival and macrocytic anemia
due to a failure of erythropoiesis. In addition to these clinically
apparent phenotypes it was later discovered that the mice have
severely diminished mast cell numbers [24]. At birth the mice still
have some remaining mast cells in for example the skin whereas
other organs such as the stomach are already entirely devoid of mast
cells. In the ﬁrst 2–3 months mast cells are also progressively lost
from the skin [24]. It is important to realize for the interpretation of
results obtained in the KitW/KitW−v or Kitlsl/Kitlsl−d mouse that the
lack of mast cells is not the only relevant immunological abnormality.
For example it has been found that the mice have important
abnormalities in their CD8+ intra epithelial lymphocytes (IEL)
[25,35]. Mice are born with normal IEL but the IEL expand 2 to 4
fold with age. There is a dramatic shift in the relative proportion of
TCRγδ positive CD8+ cells which are c-Kit positive and almost
entirely lost versus TCRαβ positive CD8+ cells which are c-Kit
negative and greatly expanded. Since these CD8+ intraepithelial
lymphocytes may play a role in anti-tumor immunosurveillance
these changes are important to consider as a potential factor other
than the absence of mast cells that can inﬂuence adenoma and cancer
development in the KitW/KitW−v and Kitlsl/Kitlsl−d mice. In addition to
the changes in IEL numbers and differentiation KitW/KitW−v also have
3,5 fold reduced numbers of intestinal lymphoid tissue inducer (LTi)
cells and half the numbers of Peyers patches of controls [6]. Thus it is
important to realize that KitW/KitW−v and Kitlsl/Kitlsl−d mice have
major abnormalities of their intestinal mucosal immune system other
than just loss of mast cells. Even more importantly, wild type bone
marrow transplantations are often used in the KitW/KitW−v mice as
proof that a certain phenotype is dependent on mast cells. Of course
the transplantation will not only correct the lack of mast cells but
also the other immunological abnormalities. Bone marrow trans-
plantations can therefore never be ﬁnal evidence for a causal role of
mast cells in the KitW/KitW−v mouse.5. Animal models of colorectal cancer development
Colon cancers develop in a well characterized sequence of events
that is termed the adenoma to carcinoma sequence. Adenomas are non
malignant frequently occurring clonal epithelial growths that are
found in around 20% of men over 50 years of age at colonoscopy [37].
Even so called advanced adenomas (N1 cm or advanced histology) are
found in around 8% of asymptomatic men over 50 years of age [37].
Given the fact that the incidence of colorectal cancer was 1.5% in the
same age group [37] the risk of progressing from a relatively large
adenoma that is grossly visible at colonoscopy to colorectal cancer can
be roughly estimated to be around 10% in this population but it is often
estimated around 5%. Studies of sporadic colon cancer development in
animalmodels depend on experimental models of adenoma incidence
and growth. To date nowidely usedmodel exists to examine adenoma
to carcinoma progression or colon cancer progression in an animal
model. However recent developmentsmayperhapsmake suchmodels
available in the near future [17]. The most frequently used models to
study adenoma development have mutations in the Adenomatous
polyposis coli (Apc) gene. APC is an important regulator of the Wnt
signaling pathway as it is required to hold together a complex of
proteins involved in the breakdown of β-catenin, the key mediator of
Wnt signaling. Many if not most human colon carcinomas have
mutations in APC. The multiple intestinal neoplasia or min mouse
(Apcmin/+) was identiﬁed in a mutagenesis screen [30]. Polyp
development in heterozygous Apc mutant mice is initiated when the
expression of the second Apc allele is lost. Polyps developmainly in the
small intestine in the Apc mutant mice which contrasts with the
situation in humans where the polyps are found in the colon, this may
also have an impact on the immunological milieu of an adenoma in
humans versusmice. The factors that govern growthof adenomas after
this initial activation of the Wnt pathway are relatively poorly
understood. Even less is known of the molecular events responsible
of the transition from a benign adenoma to an invasive colorectal
carcinoma. Thus the Apcmin/+ mouse model is a relatively good model
to study adenoma development but it is important to realize that no
conclusions can be drawn about effects on actual cancer development
from this model. An alternative is to use chemical models of
carcinogenesis such as the azoxymethane model. Azoxymethane is
an alkylating agent and metabolite of 1,2-dimethylhydrazine (DMH)
which has also been used in the past. Mice treated with DMH or
azoxymethane develop adenomas with mutations in relevant path-
ways and often have advanced histology but tumor numbers are often
low and actual invasiveness or metastasis is rare [33].
6. Mast cells and animal models of intestinal tumorigenesis
In the ﬁrst functional experiment that addressed the potential role
of mast cells in colon cancer development KitW/KitW−v mutant mice
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was started at 5–7 weeks of age, continued for 20 weeks and mice
were sacriﬁced at 30 weeks after the start of treatment. Tumors in
DMH treated control mice contained almost 20 fold more mast cells
than the unaffected mucosa indicating that mast cells may play a role
in DMH induced tumorigenesis. An average of 3.5 tumors was
observed in WBB6F1 control mice whereas congenic KitW/KitW−v
mutant mice showed only 0.5 tumors per mouse. A wild type bone
marrow transplantation increased tumor susceptibility in the KitW/
KitW−v mutant mice with an average of 2.2 tumors per mouse.
Although this was not clearly represented in a separate ﬁgure it
seemed from the frequency of polyps of different sizes that the
average size of the polyps was not signiﬁcantly different between
KitW/KitW−v mutant and control mice suggesting that mast cells
inﬂuence polyp initiation but not growth in the DMH model.
Gounaris and colleagues examined the role of mast cells in a
genetic mouse model of adenoma development. They ﬁrst showed
that mast cells accumulate in the earliest visible lesions in both Apc
mutant (Apc Δ468) mice and inducible β-catenin mutant mice which
also show constitutive activation of the Wnt pathway [14]. They
subsequently exposed their Apcmutant mice to lethal irradiation and
reconstituted the mice with wild type or KitW/KitW−v c-Kit mutant
bonemarrow.Mice reconstituted with c-Kit mutant bonemarrow had
substantially less polyps than those with wild type bone marrow.
Thus so far the data from Gounaris seemed to conﬁrm the ﬁnding in
the DMH model. It is not clear however if the high dose of irradiation
which causes a massive regenerative response in the intestinal
epithelium may have affected the role of mast cells in adenoma
development. It would have been informative if the authors had
crossed their Apc Δ468 mouse to a KitW/KitW−v background in addition
to the bone marrow transplantation.
This is especially so in the light of a third study in which KitW/
KitW−v mutant mice were crossed with the classical Apcmin/+ mouse
both on the C57/Bl6 background [40]. The resulting double mutant
mice actually developed signiﬁcantly more adenomas than the
Apcmin/+ control mouse.
Thus, three independent studies have been performed inKitW/KitW−v
mutant mice. As noted above, the KitW/KitW−v mouse model has
immunological abnormalities other than the lack of mast cells that are
all corrected by bone marrow transplantation. It can therefore not be
excluded that some of the effects of the c-Kit mutation on intestinal
polyp development are independent of the presence or absence of mast
cells. It would be interesting if a more speciﬁc mast cell deﬁcient mouse
could be made. Perhaps this could be achieved by crossing the recently
generated alpha-chymase-Cremice [32] tomicewith a conditional allele
of the Diphtheria toxin fragment A [20]. Such a mouse would allow
inducible depletion ofmast cells upon injectionswith diphtheria toxin in
analogy with similar dendritic cell conditionally depleted Cd11c-Dtr
mice [22].
The three studies show conﬂicting results that may have been
inﬂuenced by the genetic background of the mice. It was shown in the
ﬁrst study in which DMH was used that mice on a WBB6F1
background are much more sensitive to adenoma formation than
mice on a C57/Bl6 background [44] and it may be that the role of mast
cells in adenoma development depends on the genetic background of
the mouse model. Alternatively, it could be that the outcome of the
experiments has been modulated by environmental factors such as
differences in diet or in either the commensals that colonize mice in
the different facilities in which the studies were performed or more
pathogenic bacterial or viral infections which frequently occur in
mouse facilities.
A ﬁnal study that can be mentioned here is a study in which mice
lacking Glutathione S-transferase was crossed to the Apcmin/+ mouse.
The double mutant mice had a remarkable increase in polyp burden.
When mRNA proﬁles were examined between mice it was found that
lack of Glutathione S-transferase resulted in the upregulation ofproinﬂammatory cytokines and several mast cell associated proteases
and it was subsequently conﬁrmed that there was increased mast cell
inﬁltration in the double mutant mice. The mast cell inﬁltration was
therefore associated with increased polyp burden in these mice but of
course the study did not show causality [38].
7. Conclusion
There is substantial evidence to suggest that mast cells modulate
the adenoma to carcinoma sequence of colorectal cancer develop-
ment. Descriptive evidence in humans has shown that mast cells
accumulate in colorectal cancers and that densemast cell inﬁltration
is associated with a favorable outcome in patients with colon cancer.
Unfortunately there is no suitable model to study colon cancer in
animals to date and it is therefore difﬁcult to address a potential role
of mast cells in colorectal cancer. However there are several
chemical and genetic models of adenoma development and all
work in these models has conﬁrmed the accumulation of mast cells
in intestinal adenomas. As far as the role of these mast cells in the
initiation and progression of adenomas is concerned data are
conﬂicting and more work seems required to answer remaining
questions.
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